Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
NCT05971381 · View on ClinicalTrials.gov ↗
Study Summary
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
Conditions Studied
Interventions
- DEVICE RECELL® Autologous Cell Harvesting Device
Study Locations (17)
California
- University of California, Irvine — Irvine
- West Dermatology Research Center — San Diego
- Sutter Health — Sunnyvale
- California Dermatology Institute — Thousand Oaks
Michigan
- Hamzavi Dermatology — Canton
- Henry Ford Health — Detroit
- Grekin Skin Institute — Warren
Florida
- Siperstein Dermatology Group — Boynton Beach
- Skin Care Research, LLC — Hollywood
Maryland
- Dermatologic Surgery Center of Washington — Chevy Chase
- Maryland Laser, Skin & Vein Institute — Hunt Valley
New York
- The Dermatology Specialist — New York
- Mount Sinai — New York
Arizona
- Affiliated Dermatology — Scottsdale
Colorado
- Clarity Dermatology — Castle Rock
Massachusetts
- University Of Massachusetts — Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2025-01-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05971381
The ClinicalTrials.gov registry entry for NCT05971381 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avita Medical, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 1 intervention — of which RECELL® Autologous Cell Harvesting Device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05971381 reports 17 study locations spanning 9 distinct geographic areas — top geographies include California, Michigan, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05971381 about?
NCT05971381 is a clinical study titled "Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells". To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
What is the current status of trial NCT05971381?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2023-08-14. Estimated completion is 2025-01-31.
What conditions does trial NCT05971381 study?
This clinical trial studies the following conditions: Vitiligo. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05971381?
The interventions under investigation include: RECELL® Autologous Cell Harvesting Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05971381?
This trial is sponsored by Avita Medical, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05971381 being conducted?
This trial has 17 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.